合成生物学引发了抗生素开发的新时代。

Synthetic biology triggers new era of antibiotics development.

作者信息

Wang Jianfeng, Xiong Zhiqiang, Meng Hailin, Wang Yiguang, Wang Yong

机构信息

Key Laboratory of Synthetic Biology, Institute of Plant Physiology and Ecology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 300 Fenglin Road, Shanghai, 200032, China.

出版信息

Subcell Biochem. 2012;64:95-114. doi: 10.1007/978-94-007-5055-5_5.

DOI:10.1007/978-94-007-5055-5_5

PMID:23080247

Abstract

As a discipline to design and construct organisms with desired properties, synthetic biology has generated rapid progresses in the last decade. Combined synthetic biology with the traditional process, a new universal workflow for drug development has been becoming more and more attractive. The new methodology exhibits more efficient and inexpensive comparing to traditional methods in every aspect, such as new compounds discovery & screening, process design & drug manufacturing. This article reviews the application of synthetic biology in antibiotics development, including new drug discovery and screening, combinatorial biosynthesis to generate more analogues and heterologous expression of biosynthetic gene clusters with systematic engineering the recombinant microbial systems for large scale production.

摘要

作为一门设计和构建具有所需特性生物体的学科，合成生物学在过去十年中取得了迅速进展。将合成生物学与传统工艺相结合，一种新的通用药物开发工作流程变得越来越有吸引力。与传统方法相比，这种新方法在各个方面都表现得更高效、更廉价，如新化合物的发现与筛选、工艺设计与药物制造。本文综述了合成生物学在抗生素开发中的应用，包括新药发现与筛选、组合生物合成以产生更多类似物以及生物合成基因簇的异源表达，并通过系统工程改造重组微生物系统进行大规模生产。